Blog

Femovate Wins #17 - UVISA Health spotlighted in the 20 Future Danish HealthTech and MedTech Leaders report by Nelson Advisors.&nbsp;Source: <a href="https://www.linkedin.com/posts/femovate_femovate-wins-17-uvisa-health-spotlighted-activity-7446919721075261440-u9yq?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAAATkygBj_WyduhwnRCXSqwTpjlNq0tkD4g">https://www.linkedin.com/posts/femovate_femovate-wins-17-uvisa-health-spotlighted-activity-7446919721075261440-u9yq</a>"Uvisa Health is a pre-revenue medtech company developing a reusable, insertable phototherapy device to treat persistent vaginal infections. This falls under the rapidly growing "FemTech" category, which is gaining traction in 2026 as investors target underserved demographics with high earning power. Uvisa’s drug-free approach addresses the limitations of standard chemical treatments.FemTech unicorns like Flo Health are expanding into the menopause and chronic infection markets, creating a fertile environment for M&amp;A and fundraising. Uvisa’s status as an early-stage innovator with a novel delivery mechanism makes it a key company to watch in the women’s health segment of Medicon Valley."&nbsp;Wonderful to see this women's health startups next to leaders like Dawn Health: <a href="https://lnkd.in/dMJvQvPU">https://lnkd.in/dMJvQvPU</a>About the 50 Femovate Wins:&nbsp; We're sharing 50 wins from all of the amazing startups in Femovate. The wins might be investments, awards, milestone moments, and reviews from real women saying how much these products and services have impacted their lives. Because that's why Femovate exists, to improve the health of women around the world.About FemovateFemovate was created in 2022 to accelerate the investment in, and launch of, women's health innovation. Our team works closely with early stage femtech founders on product vision, go-to-market strategy, female-centered design innovation, MVP support, FDA submissions, &nbsp;clinical studies and the product development lifecycle.We launched Femovate in 2022 &nbsp;to accelerate the investment in, and launch of, women's health innovation. Since then we've invested $2M in design capital in 60 early-stage femtech startups. The startups, in turn, have launched 30 products, raised over $130 million from investment and grants, four have raised a Series A, and 7 have received FDA clearances.<a href="https://www.femovate.com/">https://www.femovate.com/</a>

Nelson Advisors referenced by Femovate, leading FemTech and Women's Health innovation accelerator

Nelson Advisors was featured by The Istituto Italiano di Tecnologia (IIT), Italian Institute of Technology, a state‑funded scientific research center based in Genoa that develops advanced technologies in robotics, computational sciences, life‑science technologies, and nanomaterials.Source: <a href="https://www.linkedin.com/feed/update/urn:li:activity:7445423260281888769/">https://www.linkedin.com/feed/update/urn:li:activity:7445423260281888769/</a>Source: <a href="https://www.facebook.com/IITalk/posts/corticale-srl-an-iit-spin-off-has-been-featured-among-the-20-future-italian-heal/1367077172121739/" data-mce-href="https://www.facebook.com/IITalk/posts/corticale-srl-an-iit-spin-off-has-been-featured-among-the-20-future-italian-heal/1367077172121739/">https://www.facebook.com/IITalk/posts/corticale-srl-an-iit-spin-off-has-been-featured-among-the-20-future-italian-heal/1367077172121739/</a>Corticale Srl, an IIT spin-off, has been featured among the "20 Future Italian HealthTech and MedTech Leaders" by Lloyd Price at Nelson Advisors.Born from IIT research, Corticale develops next-generation neurotechnology based on its #SiNAPS platform — ultra-high-density, minimally invasive neural implants capable of recording signals from thousands of neurons at single-cell resolution, enabling advanced brain-computer interfaces and new approaches to neurological disorders.This recognition highlights the impact of IIT research in translating #cuttingedgescience into real-world #healthcare #innovation.Congratulations to the Corticale team on this achievement!The Istituto Italiano di Tecnologia (IIT) IIT is a public research foundation created by the Italian government in 2003 and operational since 2005 to promote excellence in basic and applied research and support Italy’s technological and economic development. Its headquarters are in Genoa, with a network of research centers across major Italian cities (e.g., Turin, Milan, Rome, Pisa, Naples, Lecce, Venice, Ferrara) and outstations in the US (MIT and Harvard). IIT Focus&nbsp;IIT conducts multidisciplinary research focused on four main domains: robotics, computational sciences (including AI and computer vision), technologies for life sciences, and nanomaterials/nanotechnology. Their work spans humanoid and industrial robots, prosthetics and assistive devices, neuroscience and brain technologies, drug discovery, advanced imaging and microscopy, and new materials and energy solutions. IIT Mission and impact IIT’s mission is to generate high‑level scientific knowledge and turn it into real‑world technologies, with a strong emphasis on technology transfer to industry and startups. They collaborate with universities, companies, and public bodies, file patents, and create deep‑tech startups in areas such as robotics, AI, biomedicine, and advanced materials, aiming to address challenges in healthcare, sustainability, and an aging society. IIT Team and people IIT employs roughly 1,800–1,900 people from dozens of countries, with an average age around 35 and a high proportion of researchers and PhD‑level staff. The institute reports many thousands of scientific publications, hundreds of European and ERC projects, over a thousand patent titles, and several dozen established or in‑launch startupsSource: <a href="https://opentalk.iit.it/en/about-us/">https://opentalk.iit.it/en/about-us/</a>

Nelson Advisors featured by The Istituto Italiano di Tecnologia (IIT)

Nelson Advisors featured in Ingeniøren, a leading Danish Technology and Science publisher.Tyskland vil gøre sundhedsdata til motor for velfærdsteknologi:Markerer en »fundamental« omstillingTyskland tager nu et markant skridt mod en datadrevet sundheds- og plejesektor, lyder det fra rådgivningsfirmaet Nelson Advisors i en artikel.Med strategien 'GEMEINSAM DIGITAL 2026' vil det tyske sundhedsministerium udvikle deres digitale systemer fra fragmenterede datasiloer til en samlet digital infrastruktur, hvor data aktivt bruges i behandling, forskning og pleje.&nbsp;Source: <a href="https://pro.ing.dk/caretech/artikel/tyskland-vil-goere-sundhedsdata-til-motor-velfaerdsteknologi-markerer-en-fundamental-omstilling" data-mce-href="https://pro.ing.dk/caretech/artikel/tyskland-vil-goere-sundhedsdata-til-motor-velfaerdsteknologi-markerer-en-fundamental-omstilling">https://pro.ing.dk/caretech/artikel/tyskland-vil-goere-sundhedsdata-til-motor-velfaerdsteknologi-markerer-en-fundamental-omstilling</a>Germany will make health data the engine of welfare technology: Marking a "fundamental" transitionGermany is now taking a significant step towards a data-driven health and care sector, says the consulting firm Nelson Advisors in an article.With the strategy 'GEMEINSAM DIGITAL 2026', the German Ministry of Health will develop their digital systems from fragmented data silos to a unified digital infrastructure where data is actively used in treatment, research and care.<a href="https://ing.dk/">https://ing.dk/</a>Ingeniøren is widely regarded as a leading Danish niche publisher within technology and science journalism, but it is not one of the country’s general‑audience national newspapers like Politiken or Berlingske. Within the engineering, tech and science community, it is described as Denmark’s strongest and largest medium for information on technology and natural sciences, with a long history (since 1892), a large professional readership, and a flagship role in the Teknologiens Mediehus group.

Nelson Advisors featured in Ingeniøren, a leading Danish Technology and Science publisher

The European women’s health technology sector, broadly categorized as Femtech, has transitioned from a niche venture-backed experiment into a pillar of the broader digital health and medtech landscape. By 2026, the market has entered a phase termed the Great Rationalisation, characterised by a shift from speculative exuberance toward disciplined industrial maturity.&nbsp; &nbsp;&nbsp; This structural transformation has fundamentally reconfigured the investment banking landscape, shifting the center of gravity from large-cap, generalist bulge bracket institutions toward a sophisticated tier of specialist boutique advisors and a new class of financial professionals: the founder-banker.&nbsp; &nbsp;&nbsp; These individuals, often former entrepreneurs or clinicians, provide a level of operational empathy and technical fluency that career financiers struggle to replicate in an era where the value of a healthcare asset is increasingly determined by its clinical utility, regulatory resilience, and integration into existing care pathways rather than raw revenue growth.Founder Bankers in European FemTech: Nelson Advisors &nbsp;&nbsp; Among the boutique advisors serving the European market, Nelson Advisors stands out for its distinct founders for founders operational model. Unlike traditional investment banks staffed by career financiers, Nelson Advisors is led by individuals who have built, scaled and exited their own HealthTech ventures.This operational DNA allows them to align closely with the mindset of entrepreneurs navigating the complexities of their first major liquidity events. &nbsp;&nbsp; Leadership and Strategic Frameworks &nbsp;&nbsp; Lloyd Price, co-founder and partner, is a central figure in the UK and European digital health scene with over 25 years of experience. Having founded and exited multiple ventures, including Zesty (acquired by Induction Healthcare), Price possesses a rare ability to translate consumer engagement metrics into healthcare valuations, a critical skill in the B2C2B (business-to-consumer-to-business) market. His academic role as a Health Executive in Residence at UCL Global Business School for Health further cements his influence on HealthTech strategy. Paul Hemings, co-founder and partner, brings extensive corporate finance experience, including $50 billion in M&amp;A and equity transactions across global markets. His background includes co-founding Neutrally, a venture focusing on chronic lifestyle disease, which complements the firm's focus on metabolic health and longevity. Nelson Advisors employs a Build, Buy, Partner, Sell strategic framework, engaging with clients early in their lifecycle to determine the optimal strategic path for maximising shareholder value. &nbsp;&nbsp; Market Positioning and Sector Focus &nbsp;&nbsp; Nelson Advisors has emerged as a central reference point in the European HealthTech and MedTech landscape going into 2026. Their unique positioning as Strategic Architects allows them to navigate a market transitioning from growth-at-all-costs to a disciplined industrial era. They focus on high-growth verticals like healthcare AI, healthcare cybersecurity, and medical device cybersecurity. Price is frequently cited as an expert on the intersection of consumer technology and clinical pathways.Source: <a href="https://www.healthcare.digital/single-post/european-femtech-investment-banking-advisory">https://www.healthcare.digital/single-post/european-femtech-investment-banking-advisory</a>

The Strategic Evolution of European FemTech Investment Banking

Nelson Advisors has been invited to Mentor and Judge the QSTP x Merck FemTech Accelerator 2026.QSTP x Merck FemTech Accelerator 2026Qatar Science &amp; Technology Park (QSTP), a member of Qatar Foundation, in partnership with Merck, a leading science and technology company, announced the launch of the QSTP x Merck FemTech Accelerator, a dedicated accelerator designed to support deep tech and impact driven FemTech startups addressing critical unmet needs in women’s health and transforming health outcomes for women across the MENA region.The program will identify and support up to 30 leading FemTech startups developing breakthrough solutions across key women’s health domains, focusing on innovations powered by artificial intelligence, robotics, and materials science. Selected companies will receive access to advanced scaling support, market entry pathways, and clinically aligned pilot opportunities to support commercial expansion into Qatar, with pathways to scale across the wider region.Beyond supporting individual startups, the initiative is designed to generate and track measurable impact at scale, aligned with Qatar Foundation’s mission to improve women’s health outcomes across the region. Through a multi-country approach, the QSTP x Merck FemTech Accelerator will enable deep-tech startups to be piloted, validated, and adopted across multiple markets, addressing women’s health challenges at both regional and global levels.Leveraging QSTP’s innovation ecosystem and Merck’s global scientific and healthcare expertise, selected startups will benefit from curated mentorship, exposure to regional healthcare stakeholders, and opportunities to explore collaboration within Qatar’s health and research landscape. The accelerator will also facilitate engagement with relevant national institutions and ecosystem partners.Aligned with Qatar Foundation’s innovation and healthcare priorities, the accelerator aims to position the country as a regional and global hub for women’s health innovation, while addressing the urgent need for greater investment, research, and commercialization in FemTech, one of the fastest-growing and most impactful sectors in global health technology.Source: <a href="https://qstp.qa/programs/femtech/" data-mce-href="https://qstp.qa/programs/femtech/">https://qstp.qa/programs/femtech/</a>Source:&nbsp;<a href="https://qstp.qa/qstp-partners-with-merck-to-launch-femtech-accelerator-advancing-womens-health-innovation/" data-mce-href="https://qstp.qa/qstp-partners-with-merck-to-launch-femtech-accelerator-advancing-womens-health-innovation/">https://qstp.qa/qstp-partners-with-merck-to-launch-femtech-accelerator-advancing-womens-health-innovation/</a>

Nelson Advisors invited to Mentor and Judge the  QSTP x Merck FemTech Accelerator 2026

&nbsp; The final week of March and the beginning of April 2026 have been characterized by a shift toward industrial rigor and regulatory convergence. As the "Great Rationalization" of European HealthTech continues, the focus has moved from experimental AI to clinical validation and sovereign cloud infrastructure.Here are the major developments in European HealthTech for the week of March 26 – April 2, 2026:1. Major Product Launches &amp; Sovereign Cloud Adoption BD (Becton, Dickinson and Company): On April 1, 2026, BD launched its Pyxis™ Pro medication dispensing system and Incada™ Connected Care platform in Europe. AWS European Sovereign Cloud: In a significant move for data privacy, BD announced it will host these solutions on the AWS European Sovereign Cloud. This allows EU healthcare providers to meet strict digital sovereignty requirements while maintaining the scale of global cloud infrastructure. 2. Regulatory &amp; Policy Updates AI Act Integration: The European Commission updated its guidance on AI in Healthcare, focusing on aligning the new AI Act with existing MDR/IVDR (Medical Device/In Vitro Diagnostic Regulations). The goal is a "single sectoral route" for certification to prevent high-risk medical AI from needing double approval.MDR "Helsinki Procedure": New proposals are moving forward to codify the "Helsinki procedure," designed to ease bottlenecks for "borderline" products (those that sit between medical devices and other categories like cosmetics or supplements).EU HTA Machinery: The European Health Technology Assessment (HTA) framework is now fully live. Joint clinical assessments are ramping up, raising the bar for the evidence startups need to provide for pan-European market access.3. Funding &amp; Strategic InitiativesDigital Europe Programme: The EU announced a massive wave of new calls for proposals opening April 20, 2026. Key focus areas include: AI-based image screening in medical centers. Capacity building for the European Health Data Space (EHDS). Digital solutions for regulatory compliance through data. EIT Health: Launched its 2026 Innovation Validation Call, offering up to €850k (50% co-funded) for late-stage digital health projects that are ready for clinical validation and market launch. WHO &amp; Digital Wallets: On March 23, the WHO and partners launched a new initiative to expand the use of digital health wallets, aimed at making personal health records more portable across borders. 4. Biotech &amp; MedTech "Companies to Watch" Isomorphic Labs (UK): The Alphabet spin-off is reportedly preparing for its first human clinical trials using AI-designed small molecules, expected to begin later this year. Vandria (Switzerland): The clinical-stage biotech is gaining traction with its lead asset VNA-318, an oral small molecule targeting mitochondrial function for the treatment of Alzheimer's. CMR Surgical (UK): Its Versius Plus robotic platform has surpassed 40,000 procedures. The company is currently focused on its 2026 U.S. commercialization push while expanding its digital analytics suite in Europe.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&nbsp; &gt;&gt;&gt;&gt;&nbsp; &nbsp; The week of March 30 – April 2, 2026, has seen European MedTech pivot toward digital integration, regulatory simplification, and green manufacturing. While the "Great Rationalisation" of post-pandemic funding continues, the focus has shifted to the mandatory adoption of central databases and the refinement of the MDR/IVDR frameworks. Here are the major developments in European MedTech this week: 1. Regulatory "Smarter Certification" &amp; EUDAMED Deadlines European Commission Simplification: On March 31, the Commission advanced a draft regulation to simplify MDR/IVDR requirements. The most notable change is the removal of the rigid five-year certificate validity cap, moving instead toward a continuous, risk-based surveillance model. This is intended to reduce the administrative "bottleneck" that has plagued notified bodies. EUDAMED Countdown: The Commission confirmed that four key modules of the European Database on Medical Devices (EUDAMED) will become mandatory on May 28, 2026. This week, industry leaders issued a final call for firms to validate their device data, as transparency requirements will significantly increase litigation exposure and market visibility starting this summer. UK International Reliance: The MHRA (UK) launched a consultation (closing April 10, 2026) on the indefinite recognition of CE-marked devices in Great Britain. This marks a critical step in the UK's "International Reliance Framework," designed to streamline approvals for devices already cleared by the EU or US FDA. 2. Major Corporate &amp; Clinical Moves BD (Becton, Dickinson and Company): Successfully launched its Pyxis™ Pro and Incada™ Connected Careplatforms in Europe on April 1. Crucially, BD is among the first major players to host these clinical systems on the AWS European Sovereign Cloud, addressing growing EU demands for data sovereignty and local processing. Mölnlycke Health Care: On March 31, the Swedish MedTech giant issued a "Call to Action" regarding the European chronic wound crisis, coinciding with their 2025 Annual Report. The report highlights their "ProcedurePak" trays hitting the 100 million unit milestone, signaling a heavy shift toward sustainable, pre-assembled surgical kits. Johnson &amp; Johnson: Released one-year data (March 30) for ICOTYDE™, a first-in-class targeted oral peptide.While a pharmaceutical development, it is being paired with new digital adherence monitoring tools specifically designed for European market access. 3. Funding &amp; Innovation Cycles EIC Pathfinder Awards: On April 1, 2026, the European Innovation Council (EIC) awarded €118 million to 30 breakthrough research projects. A significant portion of this funding is directed toward Biotechnology for healthy ageing and Modular Multi-robot platforms for surgical assistance. Horizon Europe (Health): New calls under the HORIZON-HLTH-2026 program are now open for submission.Key areas of interest for MedTech include: Regulatory science to support patient-centered technology. New Approach Methodologies (NAMs) to replace animal testing in medical device validation. Scaling innovation in cardiovascular health, specifically targeting AI-based diagnostic wearables. 4. Sustainability &amp; Circular Economy Circular Economy Act: A coalition of 65 associations, led by MedTech Europe, issued a joint statement this week pushing for harmonized rules in the upcoming Circular Economy Act. The industry is advocating for a "Single Market, Single Rules" approach to allow for the legal refurbishment and recycling of high-value medical components across EU borders.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors referenced by Femovate, leading FemTech a...

Nelson Advisors featured by The Istituto Italiano di Tecn...

Nelson Advisors featured in Ingeniøren, a leading Danish ...

The Strategic Evolution of European FemTech Investment Ba...

Nelson Advisors invited to Mentor and Judge the QSTP x M...

This Week in European MedTech and HealthTech: 2nd April 2026